UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the date of January 30, 2023

 

Commission File Number 001-39124

 

Centogene N.V.
(Translation of registrant's name into English)

 

Am Strande 7
18055 Rostock

 

Germany
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F..X.. Form 40-F.....

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

Centogene N.V.

 

On January 30, 2023, Centogene N.V. announced an Executive Appointment.

 

A copy of the announcement is attached hereto as Exhibit 99.1.

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: January 30, 2023

 

	CENTOGENE N.V.
	By:	/s/ Jose Miguel Coego Rios
		Name:	Jose Miguel Coego Rios
		Title:	Chief Financial Officer

 

Exhibit Index

 

Exhibit	Description of Exhibit
99.1	Announcement dated January 30, 2023

 

 

Exhibit 99.1

 

CENTOGENE Announces Executive Appointment

 

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, January 30, 2023 - Centogene N.V. (the “Company”) (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that Prof. Peter Bauer, M.D., the Company’s Chief Medical and Genomic Officer, has been appointed to the Management Board of Centogene N.V. as of January 24, 2023, to be confirmed at the Company’s next General Meeting of Shareholders. Prof. Bauer has also been appointed as Managing Director of the subsidiary Centogene GmbH.

 

Prof. Bauer has been serving as CENTOGENE's Chief Medical and Genomic Officer since 2022. In this role, he combines an extensive clinical and medical understanding of genetic testing with an excellent knowledge of the latest scientific developments—turning medical questions into complete and fast analytical processes and ensuring that medically-driven results are brought to clinicians and patients immediately. Prof. Bauer originally joined CENTOGENE in 2016 and has since held a variety of management positions within the Company, including operations as well as innovation and research related roles. Prof. Bauer received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Prof. Bauer has authored more than 250 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.

 

Contact:  

 

CENTOGENE  

 

Ben Legg 

Corporate Communications 

Press@centogene.com

 

Lennart Streibel

Investor Relations

IR@centogene.com